Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.89 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.89 |
| ▸ | TUBB | P07437 | 1/20 | 0.89 |
| ▸ | YES1 | P07947 | 1/20 | 0.89 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.89 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.89 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.89 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.89 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.89 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.89 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.89 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.89 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.89 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.89 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.89 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.89 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.89 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.89 |
| ▸ | MAOB | P27338 | 6/20 | 0.77 |
| ▸ | MAOA | P21397 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Liquirtigenin SCHEMBL1071066 | 0.94 | CYP19A1 (1.00) | CYP19A1TUBB4ATUBBYES1TUBA3C | |
| Liquirtigenin SCHEMBL29552383 | 0.94 | CYP19A1 (1.00) | CYP19A1TUBB4ATUBBYES1TUBA3C | |
| Liquirtigenin SCHEMBL26970367 | 0.94 | CYP19A1 (1.00) | CYP19A1TUBB4ATUBBYES1TUBA3C | |
| Liquirtigenin SCHEMBL30352791 | 0.94 | CYP19A1 (1.00) | CYP19A1TUBB4ATUBBYES1TUBA3C | |
| Liquirtigenin SCHEMBL74552 | 0.94 | CYP19A1 (1.00) | CYP19A1TUBB4ATUBBYES1TUBA3C | |
| Liquirtigenin SCHEMBL4649862 | 0.93 | CYP19A1 (0.97) | CYP19A1TUBB4ATUBBYES1TUBA3C | |
| SCHEMBL31028354 | 0.91 | CYP19A1 (0.86) | CYP19A1TUBB4ATUBBYES1TUBA3C | |
| SCHEMBL7195893 | 0.91 | CYP19A1 (0.86) | CYP19A1TUBB4ATUBBYES1TUBA3C | |
| Liquirtigenin SCHEMBL16240337 | 0.90 | CYP19A1 (0.86) | CYP19A1TUBB4ATUBBYES1TUBA3C | |
| SCHEMBL14490032 | 0.89 | CYP19A1 (0.84) | CYP19A1TUBB4ATUBBYES1TUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150044193-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED a-SYNUCLEIN FUNCTION | NEURALTUS PHARMACEUTICALS, INC. | 2015-02-12 | — | — | US | claimed |
| US-8669048-B2 | Pluripotent cell lines and methods of use thereof | PARKINSON'S INSTITUTE (US) | 2014-03-11 | — | — | US | claimed |
| US-20130245070-A1 | COMPOUNDS FOR ENHANCING ARGINASE ACTIVITY AND METHODS OF USING SAME | THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2013-09-19 | — | — | US | claimed |
| US-20120052053-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED ALPHA-SYNUCLEIN FUNCTION | THE PARKINSON'S INSTITUTE | 2012-03-01 | — | — | US | claimed |
| EP-2361089-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED -SYNUCLEIN FUNCTION | Parkinson's Institute (US) | 2011-08-31 | — | — | EP | claimed |
| US-20100167286-A1 | Pluripotent cell lines and methods of use thereof | PARKINSON'S INSTITUTE (US) | 2010-07-01 | — | — | US | claimed |
| WO-2010056413-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED α-SYNUCLEIN FUNCTION | PARKINSON'S INSTITUTE (US) | 2010-05-20 | — | — | WO | claimed |
| US-20090253782-A1 | Compounds for Enhancing Arginase Activity and Methods of USe Thereof | CORNELL RESEARCH FOUNDATION, INC. | 2009-10-08 | — | — | US | claimed |
| WO-2008011083-A2 | COMPOUNDS FOR ENHANCING ARGINASE ACTIVITY AND METHODS OF USE THEREOF | CORNELL RESEARCH FOUNDATION, INC. (US) | 2008-01-24 | — | — | WO | claimed |
| US-10233422-B2 | Pluripotent cell lines and methods of use thereof | PARKINSON'S INSTITUTE (US) | 2019-03-19 | — | — | US | disclosed |
| US-20170114324-A1 | PLURIPOTENT CELL LINES AND METHODS OF USE THEREOF | TYLER MEDICAL RESEARCH, LLC | 2017-04-27 | — | — | US | disclosed |
| US-9464273-B2 | Pluripotent cell lines and methods of use thereof | PARKINSON'S INSTITUTE (US) | 2016-10-11 | — | — | US | disclosed |
| US-9345694-B2 | Compounds for enhancing arginase activity and methods of using same | CORNELL RESEARCH FOUNDATION, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20150044193-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED a-SYNUCLEIN FUNCTION | NEURALTUS PHARMACEUTICALS, INC. | 2015-02-12 | — | — | US | disclosed |
| WO-2010008486-A2 | PLURIPOTENT CELL LINES AND METHODS OF USE THEREOF | PARKINSONS INSTITUTE (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20090269772-A1 | SYSTEMS AND METHODS FOR IDENTIFYING COMBINATIONS OF COMPOUNDS OF THERAPEUTIC INTEREST | THERASIS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090253782-A1 | Compounds for Enhancing Arginase Activity and Methods of USe Thereof | CORNELL RESEARCH FOUNDATION, INC. | 2009-10-08 | — | — | US | disclosed |
| WO-2009065141-A1 | METHODS AND COMPOSITIONS FOR REDUCING SKIN DAMAGE | THE GENERAL HOSPITAL CORPORATION (US) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009003147-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PARKINSON'S INSTITUTE (US) | 2008-12-31 | — | — | WO | disclosed |
| WO-2008011083-A2 | COMPOUNDS FOR ENHANCING ARGINASE ACTIVITY AND METHODS OF USE THEREOF | CORNELL RESEARCH FOUNDATION, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052053-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED ALPHA-SYNUCLEIN FUNCTION | SNCA, PARK7, NLN | CYP19A1 4133/4885TUBB4A 161/4885TUBB 76/4885 |
| US-20150044193-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED a-SYNUCLEIN FUNCTION | SNCA, PARK7, NLN | CYP19A1 3865/4885TUBB4A 267/4885TUBB 134/4885 |
| US-20130245070-A1 | COMPOUNDS FOR ENHANCING ARGINASE ACTIVITY AND METHODS OF USING SAME | ARG2, ARG1, OTC | CYP19A1 2385/4885TUBB4A 1691/4885TUBB 1943/4885 |
| US-20090253782-A1 | Compounds for Enhancing Arginase Activity and Methods of USe Thereof | ARG2, ARG1, OTC | CYP19A1 2085/4885TUBB4A 1818/4885TUBB 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.